Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Frincke

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
AIDS Treatment News|May 22, 2001
HE2000 begins clinical trials: interview with James Frincke, Ph.D. Interview by John S. JamesJ Frincke
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1975
Antibodies to fentanylG L Henderson, J Frincke, C Y Leung, et al.
Annals of the New York Academy of Sciences|September 18, 2009
HE3286: a novel synthetic steroid as an oral treatment for autoimmune diseaseC Ahlem, D Auci, K Mangano, et al.
Annals of the New York Academy of Sciences|October 4, 2007
A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cellsD Auci, L Kaler, Sandhya Subramanian, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 28, 2006
Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000)C Reading, C Dowding, B Schramm, et al.
International Journal of Radiation Oncology, Biology, Physics|February 1, 1986
90Yttrium antiferritin--a new therapeutic radiolabeled antibodyS E Order, J L Klein, P K Leichner, et al.
British Journal of Cancer|April 2, 2009
Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235)R Trauger, E Corey, D Bell, et al.
Gene Therapy|February 24, 1998
Use of a novel cross-linking method to modify adenovirus tropismB E Rogers, J T Douglas, C Ahlem, et al.
Annals of the New York Academy of Sciences|August 30, 2005
Anti-inflammatory and immune regulatory properties of 5-androsten-3beta, 17beta-diol (HE2100), and synthetic analogue HE3204: implications for treatment of autoimmune diseasesD Auci, F Nicoletti, K Mangano, et al.
Journal of the National Cancer Institute|May 1, 1986
Dynamic interaction of 111indium-labeled monoclonal antibodies with surface antigens of solid tumors visualized in vivo by external scintigraphyK M Hwang, A M Keenan, J Frincke, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
AIDS Treatment News|May 22, 2001
HE2000 begins clinical trials: interview with James Frincke, Ph.D. Interview by John S. JamesJ Frincke
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1975
Antibodies to fentanylG L Henderson, J Frincke, C Y Leung, et al.
Annals of the New York Academy of Sciences|September 18, 2009
HE3286: a novel synthetic steroid as an oral treatment for autoimmune diseaseC Ahlem, D Auci, K Mangano, et al.
Annals of the New York Academy of Sciences|October 4, 2007
A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cellsD Auci, L Kaler, Sandhya Subramanian, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 28, 2006
Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000)C Reading, C Dowding, B Schramm, et al.
International Journal of Radiation Oncology, Biology, Physics|February 1, 1986
90Yttrium antiferritin--a new therapeutic radiolabeled antibodyS E Order, J L Klein, P K Leichner, et al.
British Journal of Cancer|April 2, 2009
Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235)R Trauger, E Corey, D Bell, et al.
Gene Therapy|February 24, 1998
Use of a novel cross-linking method to modify adenovirus tropismB E Rogers, J T Douglas, C Ahlem, et al.
Annals of the New York Academy of Sciences|August 30, 2005
Anti-inflammatory and immune regulatory properties of 5-androsten-3beta, 17beta-diol (HE2100), and synthetic analogue HE3204: implications for treatment of autoimmune diseasesD Auci, F Nicoletti, K Mangano, et al.
Journal of the National Cancer Institute|May 1, 1986
Dynamic interaction of 111indium-labeled monoclonal antibodies with surface antigens of solid tumors visualized in vivo by external scintigraphyK M Hwang, A M Keenan, J Frincke, et al.
Pageof 2